Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
latrodectus mactans immune globulin (equine)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Latrodectus mactans immune globulin (equine) is an equine-derived biologic antivenom developed and marketed by Merck for the treatment of systemic symptoms of black widow spider envenomation, also known as latrodectism. It is a sterile lyophilized preparation of venom-neutralizing horse immunoglobulins raised against *Latrodectus mactans* venom, historically sold under the brand name Antivenin. The antibodies bind and neutralize black widow venom toxins, principally alpha-latrotoxin, thereby preventing toxin interaction with presynaptic nerve terminals and helping reverse the severe pain, muscle spasm, autonomic manifestations, and other systemic effects associated with envenomation. Because it is a whole equine immunoglobulin product, it carries a known risk of hypersensitivity reactions including anaphylaxis and serum sickness.
- Brand names
- Antivenin
- Other names
- black widow spider antiveninblack widow spider antivenin equinelatrodectus antiveninlatrodectus mactans antiveninlatrodectus mactans immune globulin
Beyond the preview
Go deeper on latrodectus mactans immune globulin (equine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on latrodectus mactans immune globulin (equine).